Recent advances in reactive oxygen species (ROS)-responsive drug delivery systems for photodynamic therapy of cancer.
10.1016/j.apsb.2024.10.015
- Author:
Danrong HU
1
;
Yicong LI
1
;
Ran LI
1
;
Meng WANG
1
;
Kai ZHOU
2
;
Chengqi HE
1
;
Quan WEI
1
;
Zhiyong QIAN
1
Author Information
1. Rehabilitation Medicine Center and Institute of Rehabilitation Medicine, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
2. Department of Orthopedics, West China Hospital, Sichuan University, Chengdu 610041, China.
- Publication Type:Review
- Keywords:
Cancer therapy;
Drug delivery systems;
Photodynamic therapy;
ROS-responsive
- From:
Acta Pharmaceutica Sinica B
2024;14(12):5106-5131
- CountryChina
- Language:English
-
Abstract:
Reactive oxygen species (ROS)-responsive drug delivery systems (DDSs) have garnered significant attention in cancer research because of their potential for precise spatiotemporal drug release tailored to high ROS levels within tumors. Despite the challenges posed by ROS distribution heterogeneity and endogenous supply constraints, this review highlights the strategic alliance of ROS-responsive DDSs with photodynamic therapy (PDT), enabling selective drug delivery and leveraging PDT-induced ROS for enhanced therapeutic efficacy. This review delves into the biological importance of ROS in cancer progression and treatment. We elucidate in detail the operational mechanisms of ROS-responsive linkers, including thioether, thioketal, selenide, diselencide, telluride and aryl boronic acids/esters, as well as the latest developments in ROS-responsive nanomedicines that integrate with PDT strategies. These insights are intended to inspire the design of innovative ROS-responsive nanocarriers for enhanced cancer PDT.
